Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides

J Lipid Res. 2012 May;53(5):849-858. doi: 10.1194/jlr.M019844. Epub 2012 Feb 29.

Abstract

To test the hypothesis that sidedness of interfacial arginine (Arg) in apoA-I mimetic peptides, similar to that observed in apoA-I (Bashtovyy, D. et al. 2011. Sequence conservation of apolipoprotein A-I affords novel insights into HDL structure-function. J. Lipid Res. 52: 435-450.), may be important for biological activity, we compared properties of 4F and analogs, [K⁴,¹⁵>R]4F and [K⁹,¹³>R]4F, with Lys>Arg substitutions on the right and left side, respectively, of the 4F amphipathic helix. Intraperitoneal administration of these peptides into female apoE null mice (n = 13 in each group) reduced en face lesions significantly compared with controls; 4F and [K⁴,¹⁵>R]4F were equally effective whereas [K⁹,¹³>R]4F was less effective. Turnover experiments indicated that [K⁴,¹⁵>R]4F reached the highest, whereas [K⁹,¹³>R]4F had the lowest, plasma peak levels with a similar half life as the [K⁴,¹⁵>R]4F analog. The half life of 4F was two times longer than the other two peptides. The order in their abilities to associate with HDL in human plasma, generation of apoA-I particles with pre-β mobility from isolated HDL, lipid associating ability, and sensitivity of lipid complexes to trypsin digestion was: 4F>[K⁴,¹⁵,>R]4F>[K⁹,¹³>R]4F. These studies support our hypothesis that the sidedness of interfacial Arg residues in the polar face of apoA-I mimetics results in differential biological properties.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Apolipoprotein A-I / chemistry*
  • Apolipoprotein A-I / deficiency
  • Apolipoprotein A-I / genetics
  • Arginine / chemistry*
  • Aryldialkylphosphatase / metabolism
  • Atherosclerosis / blood
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / metabolism
  • Chemical Phenomena
  • Cholesterol / blood
  • Female
  • Gene Deletion
  • Guanidine / pharmacology
  • Humans
  • Lipoproteins, HDL / metabolism
  • Mice
  • Oxidation-Reduction
  • Peptidomimetics / chemistry*
  • Peptidomimetics / metabolism
  • Peptidomimetics / pharmacology*
  • Peptidomimetics / therapeutic use
  • Phosphatidylcholines / metabolism
  • Protein Structure, Secondary
  • Protein Unfolding / drug effects
  • Reactive Oxygen Species / blood
  • Unilamellar Liposomes / metabolism

Substances

  • 1-palmitoyl-2-arachidonyl-3-phosphorylcholine
  • Apolipoprotein A-I
  • Lipoproteins, HDL
  • Peptidomimetics
  • Phosphatidylcholines
  • Reactive Oxygen Species
  • Unilamellar Liposomes
  • Arginine
  • Cholesterol
  • Aryldialkylphosphatase
  • PON1 protein, mouse
  • Guanidine
  • 1-palmitoyl-2-oleoylphosphatidylcholine